LEVERKUSEN, Germany (Nov. 8, 2010)—Lanxess A.G. has agreed to acquire parts of Solutia Inc. division Flexsys' primary accelerator business and antireversion agent Perkalink 900 for an undisclosed sum.
The deal doesn't include any employees, Lanxess said, and the acquisition of the primary accelerator business requires approval from the relevant antitrust authorities.
Lanxess said it already is a major supplier of primary accelerators with its Vulkacit brand, and has invested $13.9 million during the past two years to upgrade its plant that produces the chemical in Kallo, Belgium. The firm said it will integrate the acquired accelerators business into that factory and another in Bushy Park, S.C.
The antireversion agent Perkalink 900 is one of the top products used to avoid the risk of reversion during vulcanization, thereby improving the service life of tires and other rubber products, Lanxess said. That product complements Lanxess' existing specialties line, which includes its Vulcuren antireversion agent.
Luis Lopez-Remon, head of Lanxess' rubber chemicals business, said the purchases show the firm's commitment to providing high-quality chemicals to tire and technical rubber product manufacturers. Greta Senn, president and general manager of Solutia's technical specialties division, said the sale is another step in the firm focusing Flexsys on producing rubber chemicals.
The Perkalink business represented less than 1 percent of Solutia's consolidated sales in 2009, Solutia said.